Pulmonary Arterial Hypertension: Modern, Pathway‑Directed Therapy Across Five Key Companies
PAH is a rare, progressive vasculopathy in which remodeling of small pulmonary arteries raises pulmonary vascular resistance, leading to right‑heart failure and premature death. Contemporary management targets three signaling pathways—endothelin, nitric‑oxide, and prostacyclin—as well as emerging growth‑factor signaling (activin).
Company portfolios
Drug (class / route)
Tracleer (bosentan) ERA, oral (2001) accessdata.fda.gov
Opsumit (macitentan) ERA, oral (2013) accessdata.fda.gov
Uptravi (selexipag) IP‑receptor agonist, oral(2015) accessdata.fda.gov
Adempas (riociguat) soluble‑guanylate‑cyclase stimulator, oral (2013) accessdata.fda.gov
Yutrepia (treprostinil inhalation powder) dry‑powder prostacyclin; tentatively approved (2021) accessdata.fda.gov
Winrevair (sotatercept‑csrk) activin‑signaling modulator, SC q3 weeks (approved Mar 26 2024) fda.gov
Remodulin IV/SC prostacyclin (2002) accessdata.fda.gov
Orenitram oral treprostinil ER (2013) accessdata.fda.gov
Tyvaso nebulized treprostinil (2009) and
Tyvaso DPI dry‑powder (2022) accessdata.fda.gov
Key points
Backbone agents for WHO‑FC II–III; Uptravi adds prostacyclin‑pathway effect without infusion burden.
Only drug approved for both PAH and inoperable/recurrent CTEPH; often combined with ERA.
DPI formulation designed to rival Tyvaso DPI once exclusivity barriers lift.
First disease‑modifying therapy that improves 6‑MWD and delays clinical worsening by restoring BMPR2/activin balance.
Broadest prostacyclin franchise; inhaled and oral options allow stepwise escalation.
Diagnostic considerations
PAH is confirmed by right‑heart catheterization showing mean pulmonary‑artery pressure ≥ 20 mmHg, pulmonary‑artery wedge pressure ≤ 15 mmHg, and pulmonary vascular resistance > 2 Wood units. Early referral to a specialty center enables risk‑stratified, combination therapy incorporating the agents above.
Future directions
- Triplet oral regimens combining ERA + PDE‑5/sGC + selexipag are moving up‑front.
- Sotatercept add‑on is expected to redefine low‑risk status targets.
- Inhaled gene and RNA therapies are in early trials to reverse vascular remodeling.